Display options
Cite
Sharma C, Vas AJ, Goala P, et al. Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. J Oncol. 2014;2014:321754doi: 10.1155/2014/321754.
Sharma, C., Vas, A. J., Goala, P., Gheewala, T. M., Rizvi, T. A., & Hussain, A. (2014). Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. Journal of oncology, 2014321754. https://doi.org/10.1155/2014/321754
Sharma, Chhavi, et al. "Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin." Journal of oncology vol. 2014 (2014): 321754. doi: https://doi.org/10.1155/2014/321754
Sharma C, Vas AJ, Goala P, Gheewala TM, Rizvi TA, Hussain A. Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin. J Oncol. 2014;2014:321754. doi: 10.1155/2014/321754. Epub 2014 Jan 30. PMID: 24624140; PMCID: PMC3929266.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2014;2014:321754. doi: 10.1155/2014/321754. Epub 2014 Jan 30.

Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin.

Journal of oncology

Chhavi Sharma, Andrea J Vas, Payal Goala, Taher M Gheewala, Tahir A Rizvi, Arif Hussain

Affiliations

  1. Department of Biotechnology, Manipal University, Dubai International Academic City, P.O. Box 345050, Dubai, UAE.
  2. Department of Microbiology and Immunology, Faculty of Medicine and Health Science, UAE University, P.O. Box 17666, Al Ain, UAE.

PMID: 24624140 PMCID: PMC3929266 DOI: 10.1155/2014/321754

Abstract

The present study was designed to gain insight into the antiproliferative activity of ethanolic neem leaves extract (ENLE) alone or in combination with cisplatin by cell viability assay on human breast (MCF-7) and cervical (HeLa) cancer cells. Nuclear morphological examination and cell cycle analysis were performed to determine the mode of cell death. Further, to identify its molecular targets, the expression of genes involved in apoptosis, cell cycle progression, and drug metabolism was analyzed by RT-PCR. Treatment of MCF-7, HeLa, and normal cells with ENLE differentially suppressed the growth of cancer cells in a dose- and time-dependent manner through apoptosis. Additionally, lower dose combinations of ENLE with cisplatin resulted in synergistic growth inhibition of these cells compared to the individual drugs (combination index <1). ENLE significantly modulated the expression of bax, cyclin D1, and cytochrome P450 monooxygenases (CYP 1A1 and CYP 1A2) in a time-dependent manner in these cells. Conclusively, these results emphasize the chemopreventive ability of neem alone or in combination with chemotherapeutic treatment to reduce the cytotoxic effects on normal cells, while potentiating their efficacy at lower doses. Thus, neem may be a prospective therapeutic agent to combat gynecological cancers.

References

  1. Cancer Biol Ther. 2011 Sep 15;12(6):467-76 - PubMed
  2. Free Radic Res. 2012 Jan;46(1):41-9 - PubMed
  3. J Ethnopharmacol. 2011 Apr 12;134(3):644-50 - PubMed
  4. Drug Metab Pharmacokinet. 2007 Jun;22(3):178-86 - PubMed
  5. Clin Cancer Res. 2004 Dec 1;10(23):8094-104 - PubMed
  6. Carcinogenesis. 2003 Dec;24(12):1903-11 - PubMed
  7. Oncotarget. 2012 Jan;3(1):107-11 - PubMed
  8. J Biol Chem. 2001 Jun 8;276(23):20559-65 - PubMed
  9. Mol Cancer Ther. 2006 Dec;5(12):2977-90 - PubMed
  10. Free Radic Res. 2010 Jun;44(6):624-34 - PubMed
  11. Phytother Res. 2006 Sep;20(9):814-8 - PubMed
  12. Cancer Res. 1999 Aug 15;59(16):3893-8 - PubMed
  13. Breast Cancer Res. 2002;4(1):14-7 - PubMed
  14. Chemotherapy. 2009;55(3):137-44 - PubMed
  15. Arch Gynecol Obstet. 2012 Nov;286(5):1255-9 - PubMed
  16. Asian Pac J Cancer Prev. 2002;3(3):231-238 - PubMed
  17. Life Sci. 2004 Oct 29;75(24):2867-78 - PubMed
  18. J Exp Clin Cancer Res. 2011 Sep 26;30:87 - PubMed
  19. Plant Foods Hum Nutr. 2002 Winter;57(1):53-61 - PubMed
  20. Invest New Drugs. 2009 Jun;27(3):246-52 - PubMed
  21. Asian Pac J Cancer Prev. 2005 Oct-Dec;6(4):515-20 - PubMed
  22. Invest New Drugs. 2010 Aug;28(4):392-401 - PubMed
  23. Curr Med Chem. 2008;15(23):2346-65 - PubMed
  24. Oncol Rep. 2012 Jul;28(1):291-6 - PubMed
  25. Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):467-71 - PubMed
  26. Evid Based Complement Alternat Med. 2012;2012:303019 - PubMed
  27. Hepatology. 2001 Jun;33(6):1555-7 - PubMed
  28. Food Chem Toxicol. 2008 Jul;46(7):2332-43 - PubMed
  29. Clin Cancer Res. 2005 Aug 15;11(16):6075-86 - PubMed
  30. Genes Nutr. 2011 May;6(2):149-60 - PubMed
  31. Carcinogenesis. 2011 Mar;32(3):368-80 - PubMed
  32. PLoS One. 2013;8(2):e57391 - PubMed
  33. Am J Hum Genet. 1991 Apr;48(4):720-5 - PubMed
  34. J Nat Prod. 2011 Apr 25;74(4):866-70 - PubMed
  35. Int J Oncol. 2000 Nov;17(5):869-79 - PubMed
  36. Free Radic Res. 2009 May;43(5):492-504 - PubMed
  37. Immunopharmacol Immunotoxicol. 2006;28(1):33-50 - PubMed
  38. Phytother Res. 2007 Oct;21(10):914-20 - PubMed
  39. Eur J Pharmacol. 2012 Apr 15;681(1-3):6-14 - PubMed
  40. Food Chem Toxicol. 1998 Jun;36(6):475-84 - PubMed
  41. Anticancer Res. 2011 Jan;31(1):161-70 - PubMed
  42. Life Sci. 2002 Nov 1;71(24):2845-65 - PubMed
  43. J Ethnopharmacol. 1999 Nov 1;67(2):189-95 - PubMed
  44. Front Biosci. 2004 May 01;9:1967-76 - PubMed
  45. Curr Oncol. 2007 Dec;14 Suppl 1:S3-10 - PubMed
  46. J Ethnopharmacol. 2006 Apr 21;105(1-2):246-50 - PubMed
  47. Biol Pharm Bull. 2005 Oct;28(10):1966-70 - PubMed
  48. Cancer Epidemiol. 2012 Dec;36(6):e387-93 - PubMed
  49. BMC Cancer. 2009 Jun 16;9:187 - PubMed
  50. Ther Clin Risk Manag. 2007 Jun;3(3):381-400 - PubMed

Publication Types